

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/529,745
				Filing Date	November 14, 2005
				First Named Inventor	Gustave Bergnes
				Art Unit	1624
				Examiner Name	Tamthom Ngo Truong
Sheet	1	of	1	Attorney Docket Number	09367.0085-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-6,545,004	04-08-2003	Finer et al.	
	A2	US-6,627,755	09-30-2003	Chenard et al.	
	A3	US-2002/0169159 A1	11-14-2002	Medina et al.	
	A4	US-2003/0055054 A1	03-20-2003	Medina et al.	
	A5	US-2003/0119834 A1	06-26-2003	Bamdad	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	C1	Ager et al. "Synthesis and Central Nervous System Activity of Quinazolones Related to 2-Methyl-3-(o-tolyl)-4(3H) quinazolone (Methaqualone)," <i>J. Med. Chem.</i> 20(3): 379-386 (1977).	
	C2	Coleman et al. "Inhibitors of the mitotic kinesin spindle protein" <i>Expert Opin. Ther. Patents</i> 14(12): 1659-1667 (2004)	
	C3	Rao et al. "Synthesis and Biological Activities of Certain Derivatives of 3-Aryl-4(3H)-quinazolinones, Part-II," <i>J. Indian Chem. Soc.</i> LXII: 234-237 (1985).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.